Alzheimer's Disease Imaging With PET/MRI - Beta-amyloid
| Status: | Recruiting |
|---|---|
| Conditions: | Alzheimer Disease, Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 21 - Any |
| Updated: | 4/2/2016 |
| Start Date: | October 2013 |
| End Date: | December 2016 |
| Contact: | James K O'Donnell, MD |
| Email: | Jamesk.ODonnell@UHhospitals.org |
| Phone: | (216)844-3319 |
The early detection of a preclinical AD or early stage of AD with amyloid imaging could
improve the diagnosis and provide knowledge for better therapeutical approach by combining
the best of imaging: structural MR sequences and newly FDA-approved biomarker for amyloid
PET imaging, all these two techniques with their strengths in one machine.
Specific Aims and Hypotheses can be summarized as follows:
1. To assess image quality and diagnostic performance of 18F-florbetapir (AMYVID) PET/MRI,
including direct comparison to corresponding PET/CT images of the same patients.
2. To evaluate the incremental value of using 18F-florbetapir (AMYVID) in addition to
2-[F-18]-fluoro-2 deoxy-D-glucose (FDG) versus FDG alone. Does quantification of plaque
burden correlate with degree of neuronal degeneration as depicted by FDG as well as
with clinical severity?
3. To determine plaque burden quantitatively with 18F-florbetapir (AMYVID) in PET (form
PET/CT and from PET/MR) using novel software developed specifically for these brain
application; Computer-Aid Diagnosis for Dementia for amyloid imaging - CAD4D-amyloid
improve the diagnosis and provide knowledge for better therapeutical approach by combining
the best of imaging: structural MR sequences and newly FDA-approved biomarker for amyloid
PET imaging, all these two techniques with their strengths in one machine.
Specific Aims and Hypotheses can be summarized as follows:
1. To assess image quality and diagnostic performance of 18F-florbetapir (AMYVID) PET/MRI,
including direct comparison to corresponding PET/CT images of the same patients.
2. To evaluate the incremental value of using 18F-florbetapir (AMYVID) in addition to
2-[F-18]-fluoro-2 deoxy-D-glucose (FDG) versus FDG alone. Does quantification of plaque
burden correlate with degree of neuronal degeneration as depicted by FDG as well as
with clinical severity?
3. To determine plaque burden quantitatively with 18F-florbetapir (AMYVID) in PET (form
PET/CT and from PET/MR) using novel software developed specifically for these brain
application; Computer-Aid Diagnosis for Dementia for amyloid imaging - CAD4D-amyloid
Inclusion Criteria:
- Patients with suspected AD, MCI and other cognitive impairment will be referred by
their neurologist to have a clinical ordered FDG-PET/CT and clinically indicated
AMYVID in addition,
- Patients equal to or greater than 21 years old,
- Signed informed consent by patient or legal guardian,
- Physically capable to cooperate.
Exclusion Criteria:
- Subjects who do not meet the above mentioned inclusion criteria,
- Subjects unwilling or unable to sign the informed consent form,
- Subjects with any significant psychiatric or neurologic disorder or disease other
than dementia expected to interfere with the study,
- Subjects unable to undergo MR scanning due to exclusion via UHCMC MR restrictions
(e.g. certain implanted metallic or electronic devices),
- History of adverse events related to a previous MR or PET/CT,
- Pregnant women,
- Minors.
We found this trial at
1
site
Click here to add this to my saved trials
